MicroRNA-139-5p/Flt1/Wnt/β-catenin regulatory crosstalk modulates the progression of glioma.

about

MicroRNA-139-5p/Flt1/Wnt/β-catenin regulatory crosstalk modulates the progression of glioma.

Item

http://www.wikidata.org/entity/Q47824018

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

MicroRNA-139-5p/Flt1/Wnt/β-cat ...... tes the progression of glioma.

@en

MicroRNA-139-5p/Flt1/Wnt/β-cat ...... tes the progression of glioma.

@nl

type

Item

label

MicroRNA-139-5p/Flt1/Wnt/β-cat ...... tes the progression of glioma.

@en

MicroRNA-139-5p/Flt1/Wnt/β-cat ...... tes the progression of glioma.

@nl

prefLabel

MicroRNA-139-5p/Flt1/Wnt/β-cat ...... tes the progression of glioma.

@en

MicroRNA-139-5p/Flt1/Wnt/β-cat ...... tes the progression of glioma.

@nl

P1476

MicroRNA-139-5p/Flt1/Wnt/β-cat ...... tes the progression of glioma.

@en

P2093

Bin Xu

http://www.w3.org/2001/XMLSchema#string

Chao Shang

http://www.w3.org/2001/XMLSchema#string

Jinhuan Wang

http://www.w3.org/2001/XMLSchema#string

Jixiang Du

http://www.w3.org/2001/XMLSchema#string

Qiong Wang

http://www.w3.org/2001/XMLSchema#string

Xinnv Xu

http://www.w3.org/2001/XMLSchema#string

Xiuyu Wang

http://www.w3.org/2001/XMLSchema#string

P2860

MiR-185 targets the DNA methyltransferases 1 and regulates global DNA methylation in human glioma

MicroRNAs: target recognition and regulatory functions

The biology of VEGF and its receptors

Genetic unmasking of an epigenetically silenced microRNA in human cancer cells

Wnt/β-catenin signaling regulated SATB1 promotes colorectal cancer tumorigenesis and progression

Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1

Malignant astrocytic glioma: genetics, biology, and paths to treatment

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

Vascular Endothelial Growth Factor Receptor-1 Is Synthetic Lethal to Aberrant {beta}-Catenin Activation in Colon Cancer

P304

2139-2149

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/IJMM.2018.3439

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29393392

http://www.w3.org/2001/XMLSchema#string

P932

5810245

http://www.w3.org/2001/XMLSchema#string